Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  Marion G. Peters, M.D.
Marion G. Peters, M.D.

Marion G. Peters, M.D.

Professor, Department of Medicine
John V. Carbone, M.D., Endowed Chair in Medicine
Chief of Hepatology Research

Contact Information

Appointments: (415) 353-2318
marion.peters@ucsf.edu
Open Popup
  • Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
  • St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
  • Melbourne University, M.D., 1991, Medicine/Immunology
  • 1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia
  • 1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
  • 1977-78 Gastroenterology Registrar, St. Vincent's Hospital, Melbourne, Australia
  • 1978-80 Clinical Research Fellow in Hepatology to Dr. T. B. Reynolds, University of Southern California, Los Angeles, CA
  • 1980-83 Visiting Fogarty Fellow to Dr. A.S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD
  • 1983-85 Visiting Staff Fellow to Liver Diseases Section, National Institute of Arthritis,  Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD
  • American Board of Internal Medicine, Internal Medicine
  • UCSF Liver Center
  • Member, UCSF Immunology Graduate Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Alcoholic Liver Disease
  • Autoimmune Hepatitis
  • Benign Liver Tumors
  • Cirrhosis
  • Fulminant Hepatic Failure
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Live Donor Liver Transplantation
  • Liver Transplantation
  • Nonalcoholic Fatty Liver Disease
  • Primary Biliary Cirrhosis
  • Primary Sclerosing Cholangitis
  • Liver Injury and Repair
  • Viral hepatitis and the role of the host immune response.

Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.

Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.

My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the  predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.

We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.

 

Most recent publications from a total of 172
  1. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. Clin Liver Dis. 2019 Aug; 23(3):487-492. View in PubMed
  2. Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies. Clin Liver Dis. 2019 Aug; 23(3):511-519. View in PubMed
  3. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis. 2019 Aug; 23(3):493-509. View in PubMed
  4. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. Clin Liver Dis. 2019 Aug; 23(3):521-534. View in PubMed
  5. Clarke WT, Miranda J, Neidich E, Hudock R, Peters MG, Kelly EM. Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B. J Viral Hepat. 2019 May 28. View in PubMed
  6. Nápoles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. J Public Health (Oxf). 2019 May 02. View in PubMed
  7. Peters MG. Long-Term Use of Azathioprine in the Management of Autoimmune Hepatitis. Gastroenterol Hepatol (N Y). 2019 May; 15(5):277-279. View in PubMed
  8. Lo Re V, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. J Acquir Immune Defic Syndr. 2019 Apr 29. View in PubMed
  9. Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, Levy C, Peters MG, Vierling JM, Gershwin ME. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 Jul; 101:26-34. View in PubMed
  10. Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clin Infect Dis. 2019 Mar 28. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Marion G. Peters, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

 

Site Directory
    X